Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The dilemma and promise of cancer chemoprevention.

Literature DB >> 17019426

The dilemma and promise of cancer chemoprevention.

Scott M Lippman.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2006 PMID： 17019426 DOI： 10.1038/ncponc0609

Source DB: PubMed Journal: Nat Clin Pract Oncol ISSN： 1743-4254

Keyword Cloud
Cited

× No keyword cloud information.

15 in total

Review 1. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis.

Authors: Mary E Ropka; Jess Keim; John T Philbrick
Journal: J Clin Oncol Date: 2010-05-10 Impact factor: 44.544

Review 2. DFMO: targeted risk reduction therapy for colorectal neoplasia.

Authors: Christina M Laukaitis; Eugene W Gerner
Journal: Best Pract Res Clin Gastroenterol Date: 2011-08 Impact factor: 3.043

Review 3. Suitable trial designs and cohorts for preventive breast cancer agents.

Authors: Kathrin Strasser-Weippl; Paul E Goss
Journal: Nat Rev Clin Oncol Date: 2013-10-08 Impact factor: 66.675

4. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.

Authors: Jason A Zell; Christine E McLaren; Wen-Pin Chen; Patricia A Thompson; Eugene W Gerner; Frank L Meyskens
Journal: J Natl Cancer Inst Date: 2010-08-26 Impact factor: 13.506

5. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.

Authors: Frank L Meyskens; Christine E McLaren; Daniel Pelot; Sharon Fujikawa-Brooks; Philip M Carpenter; Ernest Hawk; Gary Kelloff; Michael J Lawson; Jayashri Kidao; John McCracken; C Gregory Albers; Dennis J Ahnen; D Kim Turgeon; Steven Goldschmid; Peter Lance; Curt H Hagedorn; Daniel L Gillen; Eugene W Gerner
Journal: Cancer Prev Res (Phila) Date: 2008-06

Review 6. Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer.

Authors: Nathaniel S Rial; Jason A Zell; Alfred M Cohen; Eugene W Gerner
Journal: Expert Rev Gastroenterol Hepatol Date: 2012-08 Impact factor: 3.869

The dilemma and promise of cancer chemoprevention.

Review 1. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis.

Review 2. DFMO: targeted risk reduction therapy for colorectal neoplasia.

Review 3. Suitable trial designs and cohorts for preventive breast cancer agents.

4. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.

5. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.

Review 6. Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer.

7. Inhibitory effects of Hedyotis diffusa Willd. on colorectal cancer stem cells.

Review 8. Cancer chemoprevention locks onto a new polyamine metabolic target.

9. Metformin as an energy restriction mimetic agent for breast cancer prevention.

10. Major clinical research advances in gynecologic cancer in 2011.